

Date: April 18, 2017

To, The Manager, Listing Department, National Stock Exchange of India Limited , Exchange Plaza, C-1, Block-G, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051.	To, The Department of Corporate Service, Bombay Stock Exchange Limited , Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai - 400 001.
SYMBOL - LINCOLN	Scrp Code - 531633

Dear Sir,


SUB: STATEMENT OF INVESTOR COMPLAINTS FOR THE QUARTER ENDED ON 31ST MARCH, 2017.

Details of Investor Complaints as required under Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as below:

SR. NO.	DETAILS OF INVESTOR COMPLAINTS	NUMBER OF COMPLAINTS 3 MONTHS ENDED ON 31-03-2017
1.	No. of Investor Complaints pending at the beginning of the Quarter	NIL
2.	No. of Investor Complaints received during the Quarter	NIL
3.	No. of Investor Complaints disposed off during the Quarter	NIL
4.	No. of Investor Complaints remaining unresolved at the end of the Quarter	NIL

Kindly acknowledge the receipt of the same.

Thanking You.

Yours Faithfully,
FOR LINCOLN PHARMACEUTICALS LIMITED
MAHENDRA G. PATEL
MANAGING DIRECTOR
(DIN: 00104706)
Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-6777 8000 | **Fax :** +91-79-6777 8062
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721. Ta. : Kalol, Dist. Gandhinagar, (Guj.)
Phone : 02764-665000 | **Fax :** 02764-281809
E-mail : khatraj@lincolnpharma.com / lincoln_khatraj@rediffmail.com
